Eupraxia Pharmaceuticals Inc

Research Eupraxia Pharmaceuticals Inc (EPRX) on Bullrun: market cap CAD 608.19M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerEPRX
• ExchangeTO
• CountryCanada
• SectorHealthcare
• IndustryBiotechnology
• CurrencyCAD
• Market capCAD 608.19M
• Financial periodQ4 2025
• Net income-CAD 16.71M
• Free cash flow-CAD 9.92M

Valuation Snapshot

latest market cap is CAD 608.19M.

About Eupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis;

Frequently asked questions

What is Eupraxia Pharmaceuticals Inc's market cap?

Eupraxia Pharmaceuticals Inc's market capitalization is CAD 608.19M.

What does Eupraxia Pharmaceuticals Inc do?

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.